- self-reported symptoms of OAB for ≥ 3 months prior to screening
- OAB as defined by urinary frequency (a minimum of 8 micturitions per 24 hours)
- urgency (defined as a strong and sudden desire to urinate) or urge incontinence a
minimum of 2 episodes in 3 days, as confirmed by the micturition diary between
screening and baseline
- patients who describe the degree of bothersomeness of their most bothersome OAB
symptom as "moderately ", "a great deal ", or "a very great deal" per the OAB Bother
Rating Scale
- any condition that would contraindicate their usage of tolterodine once daily,
including: narrow angle glaucoma, urinary retention, gastric retention
- any clinically significant local urinary tract pathology which could mimic the
symptoms of OAB, such as infection or hematuria
- stress incontinence, functional, or overflow incontinence as determined by the
investigator
- symptomatic acute urinary tract infection (UTI) during the run-in period, or recurrent
UTIs defined by treatment for symptomatic UTI >3 times in the 12 months prior to
participation in this clinical trial
- clinically significant urinary tract obstruction
- history of lower urinary tract surgery (e.g. prostate removal or destruction,
incontinence surgery) within the past 3 months
- clinically significant interstitial cystitis or significant bladder pain syndrome